The decrease is a result of reducing our long-term deliveries forecast due to balance sheet constraints. We view the shares as fairly valued. Stem is off to a solid start against its 2023 guidance.

One of the largest risks I have noted with an investment in Progress is its balance sheet, which has an equity-to-asset ratio of 0.29 and a debt-to-equity ratio of 1.63.